A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Study Purpose

This is a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for up to 52 weeks.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 6 Years - 18 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

Patients meeting all of the following criteria are eligible for inclusion in this study:
  • - Written assent and informed consent must be obtained as per local regulations prior to any study procedures.
  • - Diagnosed with moderate to severe plaque psoriasis.
  • - Initiating treatment with Cosentyx® or having started Cosentyx® treatment within the last 4 weeks in routine clinical practice, and its prescription is independent of this study.
  • - Aged 6 to less than 18 years at the time they are prescribed Cosentyx®.
  • - Have valid PASI and IGA mod 2011 score at the time they are prescribed Cosentyx®.

Exclusion Criteria:

Patients meeting any of the following criteria are not eligible for inclusion in this study:
  • - Patients previously treated with other biologics.
  • - Patients participating in other clinical trials or who previously participated in clinical trials within 30 days before Cosentyx® initiation or a period of 5 half-lives of the investigational drug, whichever is longer.
  • - Patients in conditions which in the judgment of the clinical investigator renders the patient unsuitable for the study.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05388916
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Novartis Pharmaceuticals
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Novartis Pharmaceuticals
Principal Investigator Affiliation Novartis Pharmaceuticals
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Moderate to Severe Chronic Plaque Psoriasis
Additional Details

Patients who are about to initiate Cosentyx® or have started Cosentyx® within the last 4 weeks and meet the eligibility criteria will be enrolled. Patients will be followed via routine visits in real clinical practice up to 52 weeks. Data from medical records, including safety and effectiveness information of Cosentyx® (e.g., AE, SAE, physical examinations, laboratory tests, disease assessments, etc.) will be collected at each visit. No additional study visits, examinations, laboratory tests or procedures will be mandated throughout the study.

Arms & Interventions

Arms

: Cosentyx

Pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx

Interventions

Other: - Cosentyx

Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Novartis Investigative Site, Guangdong, Guangzhou, China

Status

Address

Novartis Investigative Site

Guangdong, Guangzhou, 510091

Novartis Investigative Site, Zhengzhou, Henan, China

Status

Address

Novartis Investigative Site

Zhengzhou, Henan, 450018

Novartis Investigative Site, Shenyang, Liaoning, China

Status

Address

Novartis Investigative Site

Shenyang, Liaoning, 110003

Novartis Investigative Site, Xian, Shanxi, China

Status

Address

Novartis Investigative Site

Xian, Shanxi, 710004

Novartis Investigative Site, Hangzhou, Zhejiang, China

Status

Address

Novartis Investigative Site

Hangzhou, Zhejiang, 310009

Novartis Investigative Site, Beijing, China

Status

Address

Novartis Investigative Site

Beijing, , 100069

Novartis Investigative Site, Jinan, China

Status

Address

Novartis Investigative Site

Jinan, , 250012

Novartis Investigative Site, Shijiazhuang, China

Status

Address

Novartis Investigative Site

Shijiazhuang, , 050000

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.